Research and development for new drugs and disease treatments can be lengthy and costly. Indication expansion can help broaden the impact of a new drug that has already been through the arduous R&D process for a disease or cancer. Drug repurposing can take this concept and expand on it by looking for other diseases with similar drug target biology. The logic is if they share similar target biology, they may benefit from the same treatment.

During this training, we'll cover skills such as:
• Querying QIAGEN OmicSoft Lands data from sources like TCGA or ICGC and exploring the incidence of a cancer-driving somatic mutation that is targeted by a treatment
• Creating a cohort of patients within OmicSoft with a disease-causing mutation and wild type for the gene of interest
• Generating survival curves for each mutant and wild type group for various indications in the relevant OmicSoft Land
• Using QIAGEN Ingenuity Pathway Analysis (IPA) to generate a mechanism of action network for the drug's target
• Exploring various network overlay features to enable in silico testing and combination drug partner investigation
• Searching for publicly available datasets relevant to your chosen indication
• Comparing the expression profile from our disease state with other publicly available analyses to find other indications or diseases that share similar biology